Spinal cord oligodendroglioma

Summary

Spinal cord oligodendroglioma (MONDO:0002541) is a disease. A subtype of spinal cord glioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spinal cord oligodendroglioma
Mondo ID	MONDO:0002541
DOID	DOID:3184
NCIT	C4535
SNOMED CT	254950006
UMLS	C0346295
MedGen	138055
GARD	0023157
Anatomy (UBERON)	UBERON:0002240
Is cancer (heuristic)	no

Also known as: oligodendroglioma of spinal cord · spinal cord oligodendroglioma · well differentiated spinal cord oligodendroglial tumor · well differentiated spinal cord oligodendroglial tumour · well differentiated spinal cord oligodendroglioma

Disease family

This is a subtype of spinal cord glioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › spinal cord cancer › spinal cord glioma › spinal cord oligodendroglioma

Related subtypes (3): spinal cord astrocytoma, adult spinal cord glioblastoma, ependymal tumor of spinal cord

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.